UK Interleukin Inhibitors Market
UK Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others), Forecast Period (2026-2035)
Industry Overview
UK interleukin inhibitors market was valued at $2,426.4 million in 2025 and is projected to reach $6,006.7 million by 2035, growing at a CAGR of 9.5% during the forecast period (2026–2035). The UK interleukin inhibitors market is witnessing steady growth as the National Health Service (NHS), private healthcare providers, and pharmaceutical companies increasingly rely on targeted biologic therapies for autoimmune and inflammatory diseases. Rising prevalence of rheumatoid arthritis, psoriasis, and inflammatory bowel disease, along with an emphasis on precision medicine and cost-effective treatment, is driving adoption of IL-1, IL-6, IL-17, and IL-23 inhibitors. Companies such as AbbVie, Novartis, and Janssen are actively expanding clinical trials and therapeutic indications within the UK.
Market Dynamics
Integration of Interleukin Inhibitors into Standard Treatment Protocols
The UK market is benefiting from the growing inclusion of IL inhibitors in clinical guidelines for moderate to severe autoimmune conditions. Healthcare providers are increasingly adopting these therapies for patients with inadequate response to conventional DMARDs or corticosteroids, improving treatment outcomes and long-term disease management.
Advancements in Biologics, Clinical Trials, and Patient Access
Innovation in monoclonal antibody design, real-world evidence generation, and expanded clinical programs is fueling market growth in the UK. Government initiatives supporting access to advanced therapies, combined with NHS reimbursement frameworks, are enhancing the availability and affordability of interleukin inhibitors. Ongoing collaborations between pharmaceutical companies, clinical research centers, and patient advocacy groups are further accelerating adoption, making targeted biologics a cornerstone of immunology treatment in the UK.
Market Segmentation
- Based on the product type, the market is segmented into IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors.
- Based on the application, the market is segmented into arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others.
IL-17 Inhibitors Segment to Lead the Market with the Largest Share
In the United Kingdom, IL-17 inhibitors are emerging as the dominant segment in the interleukin inhibitors market, driven by increasing adoption in chronic inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. These therapies are preferred for their targeted action, rapid symptom improvement, and long-lasting outcomes. Physician awareness, NHS-supported access, and positive evaluations from regulatory authorities such as the MHRA are reinforcing the leadership position of IL-17 inhibitors. Product innovations, including next-generation formulations and extended indications, continue to bolster market share and expand clinical utility across the UK.
Arthritis: A Key Segment in UK Market Growth
Arthritis remains a key application segment in the UK interleukin inhibitors market, driven by the prevalence of rheumatoid arthritis and other inflammatory joint disorders. IL-6 and IL-17 inhibitors are increasingly incorporated into treatment protocols for patients with moderate to severe disease who respond inadequately to conventional DMARDs. Support from the NHS, structured reimbursement schemes, and growing clinical evidence of improved patient outcomes are bolstering adoption. Expansion of specialist care networks and patient access initiatives is further accelerating growth in this segment, cementing arthritis as a major contributor to the UK interleukin inhibitors market.
Market Players Outlook
The major companies operating in the UK interleukin inhibitors market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Regeneron Pharmaceuticals, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In October 2025, GlaxoSmithKline (GSK) announced the expansion of its IL-17 inhibitor clinical program in the UK, including trials for psoriasis and psoriatic arthritis. The development aims to improve patient access and support broader adoption of biologics within NHS treatment protocols.
- In August 2025, Janssen Pharmaceuticals received NHS approval for a new IL-6 inhibitor therapy for rheumatoid arthritis, marking a milestone in expanding advanced interleukin-targeted treatments in the UK market.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the UK interleukin inhibitors
- Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- UK Interleukin Inhibitors Market Sales Analysis – Product Type | Application ($ Million)
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Interleukin Inhibitors Industry Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For UK Interleukin Inhibitors Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For UK Interleukin Inhibitors Market: Impact Analysis
- Market Opportunities
- Opportunities For UK Interleukin Inhibitors Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – UK Interleukin Inhibitors Market Revenue and Share by Manufacturers
- Interleukin Inhibitors Product Comparison Analysis
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Regeneron Pharmaceuticals, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- UK Interleukin Inhibitors Market Sales Analysis by Product Type ($ Million)
- IL-1 Inhibitors
- IL-5 Inhibitors
- IL-6 Inhibitors
- IL-17 Inhibitors
- IL-23 Inhibitors
- UK Interleukin Inhibitors Market Sales Analysis by Application ($ Million)
- Arthritis
- Asthma
- Eczema
- Inflammatory Bowel Disease (IBD)
- Psoriasis
- Others
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Samsung Bioepis Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Swedish Orphan Biovitrum AB
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. UK Interleukin Inhibitors Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. UK IL-1 Inhibitors Interleukin Inhibitors Market Research and Analysis, 2025–2035 ($ Million)
3. UK IL-5 Inhibitors Interleukin Inhibitors Market Research and Analysis, 2025–2035 ($ Million)
4. UK IL-6 Inhibitors Interleukin Inhibitors Market Research and Analysis, 2025–2035 ($ Million)
5. UK IL-17 Inhibitors Interleukin Inhibitors Market Research and Analysis, 2025–2035 ($ Million)
6. UK IL-23 Inhibitors Interleukin Inhibitors Market Research and Analysis, 2025–2035 ($ Million)
7. UK Interleukin Inhibitors Market Research and Analysis by Application, 2025–2035 ($ Million)
8. UK Interleukin Inhibitors For Arthritis Market Research and Analysis, 2025–2035 ($ Million)
9. UK Interleukin Inhibitors For Asthma Market Research and Analysis, 2025–2035 ($ Million)
10. UK Interleukin Inhibitors For Eczema Market Research and Analysis, 2025–2035 ($ Million)
11. UK Interleukin Inhibitors For Inflammatory Bowel Disease (IBD) Market Research and Analysis, 2025–2035 ($ Million)
12. UK Interleukin Inhibitors For Psoriasis Market Research and Analysis, 2025–2035 ($ Million)
13. UK Interleukin Inhibitors For Others Market Research and Analysis, 2025–2035 ($ Million)
1. UK Interleukin Inhibitors Market Share by Product Type, 2025 Vs 2035 (%)
2. UK IL-1 Inhibitors Interleukin Inhibitors Market Share, 2025 Vs 2035 (%)
3. UK IL-5 Inhibitors Interleukin Inhibitors Market Share, 2025 Vs 2035 (%)
4. UK IL-6 Inhibitors Interleukin Inhibitors Market Share, 2025 Vs 2035 (%)
5. UK IL-17 Inhibitors Interleukin Inhibitors Market Share, 2025 Vs 2035 (%)
6. UK IL-23 Inhibitors Interleukin Inhibitors Market Share, 2025 Vs 2035 (%)
7. UK Interleukin Inhibitors Market Share by Application, 2025 Vs 2035 (%)
8. UK Interleukin Inhibitors For Arthritis Market Share, 2025 Vs 2035 (%)
9. UK Interleukin Inhibitors For Asthma Market Share, 2025 Vs 2035 (%)
10. UK Interleukin Inhibitors For Eczema Market Share, 2025 Vs 2035 (%)
11. UK Interleukin Inhibitors For inflammatory Bowel Disease (IBD) Market Share, 2025 Vs 2035 (%)
12. UK Interleukin Inhibitors For Psoriasis Market Share, 2025 Vs 2035 (%)
13. UK Interleukin Inhibitors For Others Market Share, 2025 Vs 2035 (%)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the UK Interleukin Inhibitors Market in 2025 is estimated to be around $2,426.4 million.
Leading players in the UK Interleukin Inhibitors Market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Regeneron Pharmaceuticals, Inc., among others.
UK Interleukin Inhibitors Market is expected to grow at a CAGR of 9.5% from 2026 to 2035.
The UK Interleukin Inhibitors Market is growing due to rising prevalence of autoimmune and inflammatory diseases, increasing adoption of targeted biologic therapies and advancements in immunotherapy treatments.
